<VariationArchive VariationID="579997" VariationName="NM_006567.5(FARS2):c.792del (p.Asp265fs)" VariationType="Deletion" Accession="VCV000579997" Version="12" RecordType="classified" NumberOfSubmissions="6" NumberOfSubmitters="6" DateLastUpdated="2024-07-29" DateCreated="2018-10-10" MostRecentSubmission="2024-05-19">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="560904" VariationID="579997">
      <GeneList>
        <Gene Symbol="FARS2" FullName="phenylalanyl-tRNA synthetase 2, mitochondrial" GeneID="10667" HGNC_ID="HGNC:21062" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>6p25.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="6" Accession="NC_000006.12" start="5249934" stop="5771583" display_start="5249934" display_stop="5771583" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="6" Accession="NC_000006.11" start="5261583" stop="5771815" display_start="5261583" display_stop="5771815" Strand="+" />
          </Location>
          <OMIM>611592</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_006567.5(FARS2):c.792del (p.Asp265fs)</Name>
      <CanonicalSPDI>NC_000006.12:5431059:A:</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>6p25.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="6" Accession="NC_000006.12" start="5431060" stop="5431060" display_start="5431060" display_stop="5431060" variantLength="1" positionVCF="5431059" referenceAlleleVCF="TA" alternateAlleleVCF="T" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="6" Accession="NC_000006.11" start="5431293" stop="5431293" display_start="5431293" display_stop="5431293" variantLength="1" positionVCF="5431292" referenceAlleleVCF="TA" alternateAlleleVCF="T" />
      </Location>
      <ProteinChange>D265fs</ProteinChange>
      <ProteinChange>D33fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000006.11" sequenceAccession="NC_000006" sequenceVersion="11" change="g.5431293del" Assembly="GRCh37">
            <Expression>NC_000006.11:g.5431293del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_006567.3" sequenceAccession="NM_006567" sequenceVersion="3" change="c.792del">
            <Expression>NM_006567.3:c.792del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000006.12" sequenceAccession="NC_000006" sequenceVersion="12" change="g.5431060del" Assembly="GRCh38">
            <Expression>NC_000006.12:g.5431060del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_033003.2" sequenceAccession="NG_033003" sequenceVersion="2" change="g.174710del">
            <Expression>NG_033003.2:g.174710del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001318872.2" sequenceAccession="NM_001318872" sequenceVersion="2" change="c.792del">
            <Expression>NM_001318872.2:c.792del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001305801.1" sequenceAccession="NP_001305801" sequenceVersion="1" change="p.Asp265fs">
            <Expression>NP_001305801.1:p.Asp265fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001374875.1" sequenceAccession="NM_001374875" sequenceVersion="1" change="c.792del">
            <Expression>NM_001374875.1:c.792del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001361804.1" sequenceAccession="NP_001361804" sequenceVersion="1" change="p.Asp265fs">
            <Expression>NP_001361804.1:p.Asp265fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001374876.1" sequenceAccession="NM_001374876" sequenceVersion="1" change="c.792del">
            <Expression>NM_001374876.1:c.792del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001361805.1" sequenceAccession="NP_001361805" sequenceVersion="1" change="p.Asp265fs">
            <Expression>NP_001361805.1:p.Asp265fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001374877.1" sequenceAccession="NM_001374877" sequenceVersion="1" change="c.792del">
            <Expression>NM_001374877.1:c.792del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001361806.1" sequenceAccession="NP_001361806" sequenceVersion="1" change="p.Asp265fs">
            <Expression>NP_001361806.1:p.Asp265fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001374878.1" sequenceAccession="NM_001374878" sequenceVersion="1" change="c.792del">
            <Expression>NM_001374878.1:c.792del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001361807.1" sequenceAccession="NP_001361807" sequenceVersion="1" change="p.Asp265fs">
            <Expression>NP_001361807.1:p.Asp265fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001374879.1" sequenceAccession="NM_001374879" sequenceVersion="1" change="c.792del">
            <Expression>NM_001374879.1:c.792del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001361808.1" sequenceAccession="NP_001361808" sequenceVersion="1" change="p.Asp265fs">
            <Expression>NP_001361808.1:p.Asp265fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001375257.1" sequenceAccession="NM_001375257" sequenceVersion="1" change="c.792del">
            <Expression>NM_001375257.1:c.792del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001362186.1" sequenceAccession="NP_001362186" sequenceVersion="1" change="p.Asp265fs">
            <Expression>NP_001362186.1:p.Asp265fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001375259.1" sequenceAccession="NM_001375259" sequenceVersion="1" change="c.96del">
            <Expression>NM_001375259.1:c.96del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001362188.1" sequenceAccession="NP_001362188" sequenceVersion="1" change="p.Asp33fs">
            <Expression>NP_001362188.1:p.Asp33fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001375260.1" sequenceAccession="NM_001375260" sequenceVersion="1" change="c.96del">
            <Expression>NM_001375260.1:c.96del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001362189.1" sequenceAccession="NP_001362189" sequenceVersion="1" change="p.Asp33fs">
            <Expression>NP_001362189.1:p.Asp33fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_006567.5" sequenceAccession="NM_006567" sequenceVersion="5" change="c.792del" MANESelect="true">
            <Expression>NM_006567.5:c.792del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_006558.1" sequenceAccession="NP_006558" sequenceVersion="1" change="p.Asp265fs">
            <Expression>NP_006558.1:p.Asp265fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001375258.1" sequenceAccession="NM_001375258" sequenceVersion="1" change="c.772+26359del">
            <Expression>NM_001375258.1:c.772+26359del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001627" Type="intron variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_006567.5" sequenceAccession="NM_006567" sequenceVersion="5" change="c.792delA" MANESelect="true">
            <Expression>NM_006567.5:c.792delA</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="761097220" DB="dbSNP" />
      </XRefList>
      <AlleleFrequencyList>
        <AlleleFrequency Value="0.00006" Source="Trans-Omics for Precision Medicine (TOPMed)" />
        <AlleleFrequency Value="0.00007" Source="Exome Aggregation Consortium (ExAC)" />
        <AlleleFrequency Value="0.00007" Source="The Genome Aggregation Database (gnomAD), exomes" />
        <AlleleFrequency Value="0.00011" Source="The Genome Aggregation Database (gnomAD)" />
      </AlleleFrequencyList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_006567.5(FARS2):c.792del (p.Asp265fs) AND Combined oxidative phosphorylation defect type 14" Accession="RCV000703415" Version="7">
        <ClassifiedConditionList TraitSetID="9027">
          <ClassifiedCondition DB="MedGen" ID="C4755312">Combined oxidative phosphorylation defect type 14</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2024-01-22" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_006567.5(FARS2):c.792del (p.Asp265fs) AND not provided" Accession="RCV001009136" Version="1">
        <ClassifiedConditionList TraitSetID="9460">
          <ClassifiedCondition DB="MedGen" ID="C3661900">not provided</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2018-11-19" SubmissionCount="1">Likely pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_006567.5(FARS2):c.792del (p.Asp265fs) AND Inborn genetic diseases" Accession="RCV002534412" Version="2">
        <ClassifiedConditionList TraitSetID="25797">
          <ClassifiedCondition DB="MedGen" ID="C0950123">Inborn genetic diseases</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2021-04-28" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_006567.5(FARS2):c.792del (p.Asp265fs) AND Hereditary spastic paraplegia 77" Accession="RCV003994089" Version="1">
        <ClassifiedConditionList TraitSetID="31477">
          <ClassifiedCondition DB="MedGen" ID="C5569007">Hereditary spastic paraplegia 77</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2022-12-23" SubmissionCount="1">Likely pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_006567.5(FARS2):c.792del (p.Asp265fs) AND FARS2-related disorder" Accession="RCV004547874" Version="1">
        <ClassifiedConditionList TraitSetID="89978">
          <ClassifiedCondition>FARS2-related disorder</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2024-01-17" SubmissionCount="2">Pathogenic/Likely pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2024-01-22" NumberOfSubmissions="6" NumberOfSubmitters="6" DateCreated="2018-10-10" MostRecentSubmission="2024-05-19">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic/Likely pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">22833457</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">36531778</ID>
        </Citation>
        <DescriptionHistory Dated="2020-07-15">
          <Description>Conflicting classifications of pathogenicity</Description>
        </DescriptionHistory>
        <DescriptionHistory Dated="2020-03-14">
          <Description>Uncertain significance</Description>
        </DescriptionHistory>
        <ConditionList>
          <TraitSet ID="25797" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="32761" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Inborn genetic diseases</ElementValue>
              </Name>
              <Citation Type="general" Abbrev="Langer et al., 2012">
                <ID Source="PubMed">22947299</ID>
              </Citation>
              <Citation Type="general" Abbrev="SACHDNC, 2013">
                <ID Source="PubMed">23037933</ID>
              </Citation>
              <Citation Type="general" Abbrev="EASAC/FEAM, 2013">
                <ID Source="PubMed">23169492</ID>
              </Citation>
              <Citation Type="general" Abbrev="ESHG/P3G/HUGO/PHGF, 2015">
                <ID Source="PubMed">25626707</ID>
              </Citation>
              <Citation Type="general" Abbrev="Alpha-1 Foundation, 2014">
                <ID Source="PubMed">24121147</ID>
              </Citation>
              <Citation Type="general" Abbrev="NBSTRN, 2015">
                <ID Source="PubMed">24394680</ID>
              </Citation>
              <Citation Type="general" Abbrev="EUNENBS, 2014">
                <ID Source="PubMed">23652378</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2014">
                <ID Source="PubMed">23881473</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG/ACOG/NSGC/PQF/SMFM, 2015">
                <ID Source="PubMed">25730230</ID>
              </Citation>
              <Citation Type="general" Abbrev="Skirton et al., 2014">
                <ID Source="PubMed">24022298</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23619275</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACOG, 2019">
                <ID Source="PubMed">31022120</ID>
              </Citation>
              <XRef ID="C0950123" DB="MedGen" />
              <XRef ID="D030342" DB="MeSH" />
            </Trait>
          </TraitSet>
          <TraitSet ID="89978" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="70045" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">FARS2-Related Disorders</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">FARS2-related condition</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">FARS2-related disorder</ElementValue>
              </Name>
            </Trait>
          </TraitSet>
          <TraitSet ID="9460" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="17556" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">none provided</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">not provided</ElementValue>
                <XRef ID="13DG0619" DB="Department Of Translational Genomics (developmental Genetics Section), King Faisal Specialist Hospital &amp; Research Centre" />
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">The term 'not provided' is registered in MedGen to support identification of submissions to ClinVar for which no condition was named when assessing the variant. 'not provided' differs from 'not specified', which is used when a variant is asserted to be benign, likely benign, or of uncertain significance for conditions that have not been specified.</Attribute>
              </AttributeSet>
              <XRef ID="C3661900" DB="MedGen" />
            </Trait>
          </TraitSet>
          <TraitSet ID="31477" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="35839" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Spastic paraplegia 77, autosomal recessive</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Hereditary spastic paraplegia 77</ElementValue>
                <XRef ID="MONDO:0014882" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">SPG77</ElementValue>
                <XRef Type="MIM" ID="617046" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="17827" />
                <XRef ID="17827" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">The spectrum of FARS2 deficiency ranges from the infantile-onset phenotype, characterized by epileptic encephalopathy with lactic acidosis and poor prognosis (70% of affected individuals), to the later-onset phenotype, characterized by spastic paraplegia, less severe neurologic manifestations, and longer survival (30% of affected individuals). To date FARS2 deficiency has been reported in 37 individuals from 25 families. Infantile-onset phenotype. Seizures are difficult to control and may progress quickly at an early age to intractable seizures with frequent status epilepticus; some children have hypsarrhythmia on EEG. All have developmental delay; most are nonverbal and unable to walk. Feeding difficulties are common. More than half of affected children die in early childhood. Later-onset phenotype. All affected individuals have spastic paraplegia manifested by weakness, spasticity, and exaggerated reflexes of the lower extremities associated with walking difficulties; some have developmental delay/intellectual disability; some have brief seizures that resolve over time.</Attribute>
                <XRef ID="NBK538658" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">30869852</ID>
                <ID Source="BookShelf">NBK538658</ID>
              </Citation>
              <XRef ID="466722" DB="Orphanet" />
              <XRef ID="C5569007" DB="MedGen" />
              <XRef ID="MONDO:0014882" DB="MONDO" />
              <XRef Type="MIM" ID="617046" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="9027" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="17497" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Combined oxidative phosphorylation deficiency 14</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Combined oxidative phosphorylation defect type 14</ElementValue>
                <XRef ID="MONDO:0013986" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">COXPD14</ElementValue>
                <XRef Type="MIM" ID="614946" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="17455" />
                <XRef ID="17455" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">The spectrum of FARS2 deficiency ranges from the infantile-onset phenotype, characterized by epileptic encephalopathy with lactic acidosis and poor prognosis (70% of affected individuals), to the later-onset phenotype, characterized by spastic paraplegia, less severe neurologic manifestations, and longer survival (30% of affected individuals). To date FARS2 deficiency has been reported in 37 individuals from 25 families. Infantile-onset phenotype. Seizures are difficult to control and may progress quickly at an early age to intractable seizures with frequent status epilepticus; some children have hypsarrhythmia on EEG. All have developmental delay; most are nonverbal and unable to walk. Feeding difficulties are common. More than half of affected children die in early childhood. Later-onset phenotype. All affected individuals have spastic paraplegia manifested by weakness, spasticity, and exaggerated reflexes of the lower extremities associated with walking difficulties; some have developmental delay/intellectual disability; some have brief seizures that resolve over time.</Attribute>
                <XRef ID="NBK538658" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">30869852</ID>
                <ID Source="BookShelf">NBK538658</ID>
              </Citation>
              <XRef ID="319519" DB="Orphanet" />
              <XRef ID="C4755312" DB="MedGen" />
              <XRef ID="MONDO:0013986" DB="MONDO" />
              <XRef Type="MIM" ID="614946" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="1604243" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-14" DateCreated="2018-10-10">
        <ClinVarSubmissionID localKey="3123785|MedGen:C3554168" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000832313" DateUpdated="2024-02-14" DateCreated="2018-10-10" Type="SCV" Version="7" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2024-01-22">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">22833457</ID>
          </Citation>
          <Comment>This sequence change creates a premature translational stop signal (p.Asp265Thrfs*29) in the FARS2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in FARS2 are known to be pathogenic (PMID: 22833457). This variant is present in population databases (rs761097220, gnomAD 0.01%). This variant has not been reported in the literature in individuals affected with FARS2-related conditions. ClinVar contains an entry for this variant (Variation ID: 579997). For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="FARS2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000006.11:g.5431293del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C3554168" Type="CUI" />
          </Trait>
        </TraitSet>
        <Citation Type="general">
          <ID Source="PubMed">28492532</ID>
        </Citation>
        <SubmissionNameList>
          <SubmissionName>SUB11431369</SubmissionName>
          <SubmissionName>SUB12507860</SubmissionName>
          <SubmissionName>SUB14200283</SubmissionName>
          <SubmissionName>SUB8755776</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2306944" SubmissionDate="2019-10-15" DateLastUpdated="2020-03-16" DateCreated="2020-03-16">
        <ClinVarSubmissionID localKey="GDX:2591031|Not Provided" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001168951" DateUpdated="2020-03-16" DateCreated="2020-03-16" Type="SCV" Version="1" SubmitterName="GeneDx" OrgID="26957" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2018-11-19">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Likely pathogenic</GermlineClassification>
          <Comment>The c.792delA variant in the FARS2 gene has not been reported previously as a pathogenic variant nor as a benign variant, to our knowledge. The c.792delA variant causes a frameshift starting with codon Aspartic acid 265, changes this amino acid to a Threonine residue, and creates a premature Stop codon at position 29 of the new reading frame, denoted p.Asp265ThrfsX29. This variant is predicted to cause loss of normal protein function either through protein truncation or nonsense-mediated mRNA decay. The c.792delA variant is observed in 18/126508 (0.014%) alleles from individuals of non-Finnish European background, although not seen in the homozygous state, in large population cohorts (Lek et al., 2016). We interpret c.792delA as a likely pathogenic variant.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">GeneDx Variant Classification (06012015)</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/dhtz9flo/genedx_interprules_final_061215.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="FARS2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_006567.3:c.792delA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Not Provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB6425168</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7354546" SubmissionDate="2023-06-21" DateLastUpdated="2023-06-24" DateCreated="2023-06-24">
        <ClinVarSubmissionID localKey="NM_006567.4:c.792delA|FARS2-Related Disorders" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV003933846" DateUpdated="2023-06-24" DateCreated="2023-06-24" Type="SCV" Version="1" SubmitterName="Women's Health and Genetics/Laboratory Corporation of America, LabCorp" OrgID="500026" OrganizationCategory="laboratory" OrgAbbreviation="WHG-LC" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-05-23">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">36531778</ID>
          </Citation>
          <Comment>Variant summary: FARS2 c.792delA (p.Asp265ThrfsX29) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. The variant allele was found at a frequency of 6.8e-05 in 251200 control chromosomes (gnomAD). c.792delA has been reported in the literature in an individual affected with FARS2-Related Disorders (example: Guerrero_2021). The following publication has been ascertained in the context of this evaluation (PMID: 36531778). Three clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 and all classified the variant as pathogenic/likely pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">LabCorp Variant Classification Summary - May 2015</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/api/2.0/files/rtxspsnt/labcorp_variant_classification_method_-_may_2015.pdf/?format=attachment</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="FARS2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_006567.4:c.792delA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">FARS2-Related Disorders</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB13562035</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="6394905" SubmissionDate="2024-04-19" DateLastUpdated="2024-05-01" DateCreated="2023-02-07">
        <ClinVarSubmissionID localKey="a360939|MedGen:C0950123" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV003714553" DateUpdated="2024-05-01" DateCreated="2023-02-07" Type="SCV" Version="2" SubmitterName="Ambry Genetics" OrgID="61756" OrganizationCategory="laboratory" OrgAbbreviation="Ambry" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-04-28">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>The c.792delA (p.D265Tfs*29) alteration, located in exon 4 (coding exon 3) of the FARS2 gene, consists of a deletion of one nucleotide at position 792, causing a translational frameshift with a predicted alternate stop codon after 29 amino acids. This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. This alteration was reported in the compound heterozygous state with a missense alteration in an individual with neurodevelopmental impairment, gait disturbance, slowly progressive spastic quadriparesis, brisk reflexes, impaired pain sensation, enlarged cisterna magna, hip dysplasia, deviated hallux, 2-3 toe syndactyly, and tapered finger (DECIPHER v.9.32). Based on the available evidence, this alteration is classified as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Ambry Variant Classification Scheme 2023</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/api/2.0/files/i9igeqse/ambry_variant_classification_scheme_2023.pdf/?format=attachment</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="FARS2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_006567.3:c.792delA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0950123" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>AVA4 Submission_Through01042023</SubmissionName>
          <SubmissionName>FinalClinVarSubmissionFile_20140101to20240315_ava4_1</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="8997603" SubmissionDate="2024-04-12" DateLastUpdated="2024-04-15" DateCreated="2024-04-15">
        <ClinVarSubmissionID localKey="rmh/unit_1/hg38_NM_006567_5_FARS2_c_792delA" localKeyIsSubmitted="1" />
        <ClinVarAccession Accession="SCV004812780" DateUpdated="2024-04-15" DateCreated="2024-04-15" Type="SCV" Version="1" SubmitterName="Molecular Genetics, Royal Melbourne Hospital" OrgID="508231" OrganizationCategory="laboratory" OrgAbbreviation="RMH" />
        <AdditionalSubmitters>
          <SubmitterDescription OrgID="508197" SubmitterName="Shariant Australia, Australian Genomics" Type="behalf" OrganizationCategory="consortium" />
        </AdditionalSubmitters>
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-12-23">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Likely pathogenic</GermlineClassification>
          <Comment>This sequence change in FARS2 is a frameshift variant predicted to cause a premature stop codon, p.(Asp265Thrfs*29), in biologically relevant exon 4/7 leading to nonsense-mediated decay in a gene in which loss-of-function is an established disease mechanism. The highest population minor allele frequency in the population database gnomAD v2.1 is 0.01% (19/128,978 alleles) in the European (non-Finnish) population, which is consistent with recessive disease. To our knowledge, this variant has not been reported in the relevant scientific literature in any individuals with FARS2-related disease. Based on the classification scheme RMH Modified ACMG Guidelines v1.5.1, this variant is classified as LIKELY PATHOGENIC. Following criteria are met: PVS1, PM2_Supporting.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="FARS2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="SubmitterVariantId">ALLELE_18534</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_006567.5:c.792delA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MONDO" ID="MONDO:0014882" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>submission_41</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="9790925" SubmissionDate="2024-05-09" DateLastUpdated="2024-05-19" DateCreated="2024-05-19">
        <ClinVarSubmissionID localKey="53626772|FARS2-related disorder" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV005043994" DateUpdated="2024-05-19" DateCreated="2024-05-19" Type="SCV" Version="1" SubmitterName="Greenwood Genetic Center Diagnostic Laboratories, Greenwood Genetic Center" OrgID="1019" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2024-01-17">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Likely pathogenic</GermlineClassification>
          <Comment>PVS1, PM2</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="FARS2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_006567.5:c.792del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">FARS2-related disorder</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB14430613</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="7354546" TraitType="Disease" MappingType="Name" MappingValue="FARS2-Related Disorders" MappingRef="Preferred">
        <MedGen CUI="None" Name="FARS2-related disorder" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1604243" TraitType="Disease" MappingType="XRef" MappingValue="C3554168" MappingRef="MedGen">
        <MedGen CUI="C4755312" Name="Combined oxidative phosphorylation defect type 14" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="6394905" TraitType="Disease" MappingType="XRef" MappingValue="C0950123" MappingRef="MedGen">
        <MedGen CUI="C0950123" Name="Inborn genetic diseases" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="8997603" TraitType="Disease" MappingType="XRef" MappingValue="MONDO:0014882" MappingRef="MONDO">
        <MedGen CUI="C5569007" Name="Hereditary spastic paraplegia 77" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="9790925" TraitType="Disease" MappingType="Name" MappingValue="FARS2-related disorder" MappingRef="Preferred">
        <MedGen CUI="None" Name="FARS2-related disorder" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2306944" TraitType="Disease" MappingType="Name" MappingValue="Not Provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

